SAN FRANCISCO, Sept. 27, 2011 /CNW/ - Biosign Technologies Inc. (TSXV:
BIO) a medical device company focused on non-invasive, cloud-based
vital health monitoring, sponsored the "In Conversation with 3 CEO's"
panel featuring Anne Wojcicki of 23andme, Sona Mehring of Caring
Bridge, and West Shell of Healthline at the Health 2.0 Conference.
Biosign, CEO, Dr. Scott Jenkins is scheduled to introduce the panel to
over 1,000 attendees and demonstrate the Cloud DxTM solution that enables providers to deliver quality care utilizing the
UFIT® device and remote cloud monitoring systems.
Health 2.0 is known for showcasing innovative healthcare technology and
bringing together the industry's top thought leaders. Biosign was
invited as 1 of 10 businesses to meet with key investors and decision
makers at healthcare organizations, like United Health Group,
California Health Care Foundation, Interwest Partners, the U.S.
Government, and AT&T ForHealthSM to discuss the Cloud DxTM solution.
"It was an honor to be selected in the first ever Matchpoint! at Health
2.0. Considering the criteria for selection indicated an interest in
investment, partnering or pilots - this is a very exciting time for us
as a company," said Dr. Jenkins, CEO, Bisosign.
UFIT® combines the power of the cloud for validation and analysis with
an easy to use wrist cuff for pain-free non-invasive measurement of
vital health information. Measuring both blood glucose and blood
pressure from a single device makes this application unique. Biosign
offers additional data analysis services through their Cloud DxTM solution.
Biosign agreed to provide the opportunity for anyone attending Health
2.0 to take their own readings at a special station. The device is not
yet approved by the FDA for sale in the U.S., but allowing people to
experience how the UFIT® medical device works is the first step to
getting the disruptive but necessary Cloud DxTM solution into the hands of patients and doctors.
About Cloud DxTM
The Cloud DxTM brand is a trademark of Biosign Technologies Inc. under which Biosign
delivers services to consumers, healthcare professionals and payers.
Biosign collects data from proprietary non-invasive devices, uses the
cloud for validation, analysis and synthesis of the data, and then
makes the information available to patients and their Circle of CareTM. We believe Cloud DxTM is the future of remote healthcare monitoring and quality patient care.
For more information, please visit: www.1000billionreasons.com and www.clouddx.com.
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems
through its Cloud DxTM branded solution. Cloud DxTM applications include intelligent systems for non-invasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. Biosign technology combines measurement, analysis, and
tools for disease and patient management to support global vital health
monitoring. The UFIT® medical device delivers quality data collection
and analytics for clinical diagnostics, self-care, wellness, disease
state evaluation and management, and remote patient monitoring. For
more information visit: www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Biosign/Cloud Dx Contact: